Fibroblast Growth Factor 23 and αklotho in Acute Kidney Injury: Current Status in Diagnostic and Therapeutic Applications

12Citations
Citations of this article
16Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Fibroblast growth factor (FGF) 23 and αKlotho are circulating mineral regulatory substances that also have a very diverse range of actions. Acute kidney injury (AKI) is a state of high FGF23 and low αKlotho. Clinical association data for FGF23 are strong, but the basic pathobiology of FGF23 in AKI is rather sparse. Conversely, preclinical data supporting a pathogenic role of αKlotho in AKI are strong, but the human data are still being generated. This pair of substances can potentially serve as diagnostic and prognostic biomarkers. FGF23 blockade and αKlotho restoration can have prophylactic and therapeutic utility in AKI. The literature to date is briefly reviewed in this article.

Cite

CITATION STYLE

APA

Neyra, J. A., Hu, M. C., & Moe, O. W. (2020, December 1). Fibroblast Growth Factor 23 and αklotho in Acute Kidney Injury: Current Status in Diagnostic and Therapeutic Applications. Nephron. S. Karger AG. https://doi.org/10.1159/000509856

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free